Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted to evaluate the efficacy and safety of radotinib as first-line therapy for CML-CP. Experimental Design: This multinational, open-label study assigned patients (1:1:1) to one of two twice-daily radotinib doses, or imatinib daily. The primary endpoint was major molecular response (MMR) by 12 months. Results: Two hundred forty-one patients were randomized to receive radotinib 300 mg (n = 79) or 400 mg twice-daily (n = 81), or imatinib 400 mg daily (n = 81). MMR rates by 12 months were higher in patients receiving radotinib 300 mg (52%) or radotinib 400 mg twice-daily (46%) versus imatinib (30%; P = 0.0044 and P = 0.0342, respectively). Complete cytogenetic response (CCyR) rates by 12 months were higher for radotinib 300 mg (91%) versus imatinib (77%; P = 0.0120). Early molecular response at 3 months occurred in 86% and 87% of patients receiving radotinib 300 mg and radotinib 400 mg, respectively, and 71% of those receiving imatinib. By 12 months, no patients had progression to accelerated phase or blast crisis. Most adverse events were manageable with dose reduction. Conclusions: Radotinib demonstrated superiority over imatinib in CCyR and MMR in patients newly diagnosed with Philadelphia chromosome–positive CML-CP. This trial was registered at www.clinicaltrials.gov as NCT01511289. Clin Cancer Res; 23(23); 7180–8. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Cited by
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
“The registration trial (RERISE) [45] and the 4-year update [56] indicated that molecular response rates were significantly higher with radotinib at 300 mg twice daily than with imatinib.”
BackgroundSelf-citationSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling
Heo, S.-K., Noh, E.-K., Seo, H. J., Lee, Y. J., Koh, S., Min, Y. J., Choi, Y., & Jo, J.-C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0265958 · Cited by 11
Shin, D.-Y., Park, S., Jang, E., Kong, J. H., Won, Y.-W., Oh, S., Choi, Y., Kim, J.-A., Lee, S. W., Mun, Y.-C., et al. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107542 · Cited by 3
Self-citation
Metadata
- Authors
- Kwak, J.-Y., Kim, S.-H., Oh, S. J., Zang, D. Y., Kim, H., Kim, J.-A., Do, Y. R., Kim, H. J., Park, J. S., Choi, C. W., Lee, W. S., Mun, Y.-C., Kong, J. H., Chung, J. S., Shin, H.-J., Kim, D.-Y., Park, J., Jung, C. W., Bunworasate, U., Comia, N. S., Jootar, S., Reksodiputro, A. H., Caguioa, P. B., Lee, S.-E., & Kim, D.-W.
- Venue
- Clinical Cancer Research
- Published
- 2017-11-30
- Volume
- 23
- Issue
- 23
- Pages
- 7180-7188
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2759146932
- Cited by
- 78
- References
- 2
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0957
- The paper
- Kwak, J.-Y., Kim, S.-H., Oh, S. J., Zang, D. Y., Kim, H., Kim, J.-A., Do, Y. R., Kim, H. J., Park, J. S., Choi, C. W., Lee, W. S., Mun, Y.-C., Kong, J. H., Chung, J. S., Shin, H.-J., Kim, D.-Y., Park, J., Jung, C. W., Bunworasate, U., . . . Kim, D.-W. (2017). Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0957
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.